CIFOBAN (Fresenius Medical Care Australia Pty Ltd)
Product name
CIFOBAN
Date registered
Evaluation commenced
Decision date
Approval time
252 (255 working days)
Active ingredients
sodium citrate dihydrate
Registration type
NCE/NBE
Indication
Cifoban is used for regional citrate anticoagulation (RCA) in continuous venovenous haemodialysis (CVVHD), continuous venovenous haemodiafiltration (CVVHDF), sustained low efficiency (daily) dialysis (SLEDD) and therapeutic plasma exchange (TPE) via membrane plasma separation.
Cifoban is indicated in adults and children of all age groups (except preterm newborn infants).